Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Pre-Mkt 03-03 08:04:15 EST

101.62

-0.40

-0.39%

盘前100.01

-1.61-1.58%

08:02 EST

High102.34	Low97.78	Vol2.48M
Open101.50	D1 Closing102.02	Amplitude4.47%
Mkt Cap20.14B	Tradable Cap18.19B	Total Shares198.17M
T/O250.68M	T/O Rate1.38%	Tradable Shares179.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":101.62,"timestamp":1772485200000,"preClose":102.02,"halted":0,"volume":2475475,"hourTrading":{"tag":"盘前","latestPrice":100.01,"preClose":101.62,"latestTime":"08:02 EST","volume":220,"amount":21804.01212,"timestamp":1772542942062,"change":-1.61,"changeRate":-0.015843,"amplitude":0.021439},"delay":0,"changeRate":-0.003920799843167923,"floatShares":179000000,"shares":198173397,"eps":-5.95,"marketStatus":"Pre-Mkt","change":-0.4,"latestTime":"03-03 08:04:15 EST","open":101.5,"high":102.34,"low":97.78,"amount":250677822.30365,"amplitude":0.044697,"askPrice":101.5,"askSize":52,"bidPrice":100,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772548200000},"marketStatusCode":1,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":101.62,"preHourTrading":{"tag":"盘前","latestPrice":100.01,"preClose":101.62,"latestTime":"08:02 EST","volume":220,"amount":21804.01212,"timestamp":1772542942062,"change":-1.61,"changeRate":-0.015843,"amplitude":0.021439},"postHourTrading":{"tag":"盘后","latestPrice":100.76,"preClose":101.62,"latestTime":"19:04 EST","volume":20431,"amount":2075982.3068,"timestamp":1772496295818,"change":-0.86,"changeRate":-0.008463,"amplitude":0.008561},"volumeRatio":0.6602651286747208,"impliedVol":0.7846,"impliedVolPercentile":0.976},"requestUrl":"/m/hq/s/RVMD/tweets","defaultTab":"tweets","newsList":[{"id":"2616398550","title":"Revolution Medicines Doubles Down on Costly RAS Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2616398550","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616398550?lang=en_us&edition=fundamental","pubTime":"2026-03-03 08:17","pubTimestamp":1772497066,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. (($RVMD)) has held its Q4 earnings call. Read on for the main highlights of the call. Revolution Medicines’ latest earni...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-doubles-down-on-costly-ras-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-doubles-down-on-costly-ras-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2614886909","title":"Revolution Medicines put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614886909?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:55","pubTimestamp":1772218516,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Revolution Medicines (RVMD) with 3,163 puts trading, or 1.0x expected. Most active are Mar-26 90 puts and Mar-26 105 puts, wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2614886363","title":"Revolution's Daraxonrasib has 'Blockbuster' Potential, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886363","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614886363?lang=en_us&edition=fundamental","pubTime":"2026-02-28 00:23","pubTimestamp":1772209435,"startTime":"0","endTime":"0","summary":"Revolution Medicines'  daraxonrasib has \"blockbuster\" potential in the pancreatic ductal adenocarcinoma, or PDAC, market, UBS said in a Friday note.\"We think daraxonrasib has blockbuster potential in PDAC alone,\" the report said.The note said PDAC is a difficult market with few options for patients and where a novel overall survival-modifying treatment could have real impact and $6 billion to $7 billion sales potential.A key catalyst will be the readout of late-stage trial results of daraxonrasib in patients with second line metastatic disease in the first half of 2026, the report said.\"We see 70-80% PoS of a positive readout here for lead asset daraxonrasib,\" the note said. PoS refers to probability of success.UBS has a buy rating on the stock and a $145 price target.Price: 101.93, Change: -0.22, Percent Change: -0.22","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2614304518","title":"Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614304518","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614304518?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:56","pubTimestamp":1772193408,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $132.16, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"gpt_icon":0},{"id":"2614002089","title":"Tango Therapeutics weakness an ‘over reaction,’ says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2614002089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614002089?lang=en_us&edition=fundamental","pubTime":"2026-02-27 02:28","pubTimestamp":1772130483,"startTime":"0","endTime":"0","summary":"Stifel believes Tango Therapeutics (TNGX) shares are reacting in large part due to Revolution Medicines’ (RVMD) announcement of a clinical trial co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-weakness-an-over-reaction-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-weakness-an-over-reaction-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNGX","RVMD","LENZ","BK4139","BK4007","BK4539","SF","BK4127"],"gpt_icon":0},{"id":"2614429350","title":"Revolution Medicines Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2614429350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614429350?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:22","pubTimestamp":1772112120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 08:22 ET (13:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"gpt_icon":0},{"id":"2614042654","title":"Revolution Medicines (RVMD) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2614042654","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614042654?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:16","pubTimestamp":1772111772,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Revolution Medicines, with a price target of $147.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2614041770","title":"Revolution Medicines price target raised to $115 from $109 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041770?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:52","pubTimestamp":1772110361,"startTime":"0","endTime":"0","summary":"BofA analyst Alex Stranahan raised the firm’s price target on Revolution Medicines (RVMD) to $115 from $109 and keeps a Buy rating on the shares. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-115-from-109-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-115-from-109-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"gpt_icon":0},{"id":"2614404394","title":"Mizuho Trims Price Target on Revolution Medicines to $140 From $143, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614404394","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614404394?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:40","pubTimestamp":1772106008,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $127.47, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","RVMD"],"gpt_icon":0},{"id":"2614436980","title":"Revolution Medicines price target raised to $144 from $100 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2614436980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614436980?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:29","pubTimestamp":1772105396,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Revolution Medicines (RVMD) to $144 from $100 and keeps an Overweight rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-144-from-100-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-144-from-100-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"gpt_icon":0},{"id":"2614062819","title":"Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN), Mirum Pharmaceuticals (MIRM) and Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614062819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614062819?lang=en_us&edition=fundamental","pubTime":"2026-02-26 10:30","pubTimestamp":1772073016,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medline, Inc. Class A (MDLN – Research Report), Miru...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-medline-inc-class-a-mdln-mirum-pharmaceuticals-mirm-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-medline-inc-class-a-mdln-mirum-pharmaceuticals-mirm-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","MDLN","BK4139","RVMD","MIRM","LABU","XLV","BK4198","BK4588","LU0029874061.USD","HCSG","LU0128526141.USD","BK4581","XBI","BK4585"],"gpt_icon":0},{"id":"2614062852","title":"Revolution Medicines: Advancing RAS Inhibitor Pipeline and Strong Cash Runway Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614062852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614062852?lang=en_us&edition=fundamental","pubTime":"2026-02-26 10:25","pubTimestamp":1772072733,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm has maintained their bullish stance on RVMD stock, giving a Buy rating yesterday. Marc Frahm has given his Buy rating d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/revolution-medicines-advancing-ras-inhibitor-pipeline-and-strong-cash-runway-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/revolution-medicines-advancing-ras-inhibitor-pipeline-and-strong-cash-runway-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"gpt_icon":0},{"id":"2614050251","title":"BRIEF-Revolution Medicines Inc Files For Common Stock Offering Of Up To $1.0 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050251","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050251?lang=en_us&edition=fundamental","pubTime":"2026-02-26 07:17","pubTimestamp":1772061465,"startTime":"0","endTime":"0","summary":"BRIEF-Revolution Medicines Inc Files For Common Stock Offering Of Up To $1.0 BillionFeb 25 (Reuters) - Revolution Medicines Inc RVMD.O:REVOLUTION MEDICINES INC FILES FOR COMMON STOCK OFFERING OF UP TO $1.0 BILLION - SEC FILINGFurther company coverage: RVMD.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL23R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"1160968591","title":"Stock Track | Revolution Medicines Plunges 7.98% After-Hours on Earnings Miss and $1 Billion Stock Offering Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1160968591","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160968591?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:12","pubTimestamp":1772057566,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. (RVMD) experienced a significant after-hours plunge of 7.98% on Wednesday, following the release of its fourth-quarter financial results and a new capital-raising plan.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RVMD"],"gpt_icon":0},{"id":"2614052367","title":"Revolution Medicines Inc Files for Common Stock Offering of up to $1.0 Bln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2614052367","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614052367?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:08","pubTimestamp":1772057309,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL23R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2614590760","title":"Earnings Flash (RVMD) Revolution Medicines Posts Q4 Loss $1.86, vs. FactSet Est of $1.58 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2614590760","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614590760?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:24","pubTimestamp":1772054655,"startTime":"0","endTime":"0","summary":"Earnings Flash (RVMD) Revolution Medicines Posts Q4 Loss $1.86, vs. FactSet Est of $1.58 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"gpt_icon":0},{"id":"2614476056","title":"Revolution Medicines Publishes Corporate Presentation on RAS(ON) Inhibitors to Outsmart Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2614476056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614476056?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:13","pubTimestamp":1772053998,"startTime":"0","endTime":"0","summary":"Revolution Medicines Inc. released a corporate presentation outlining its oncology pipeline focused on RAS inhibitors across pancreatic cancer, non-small cell lung cancer and colorectal cancer. The company highlighted four clinical-stage investigational drugs: daraxonrasib, zoldonrasib, elironrasib and RMC-5127, and described multiple randomized Phase 3 registrational trials active or planned for 2026, including RASolute studies in pancreatic cancer and RASolve studies in lung cancer. The presentation also noted combination-development efforts in colorectal cancer, including RAS inhibitor doublets and other combination approaches, and reported cash and investments of $2.0 billion as of Dec. 31, 2025, with additional committed capital referenced. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL6zhCLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2614059950","title":"Revolution Medicines reports Q4 EPS ($1.86), consensus ($1.56)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614059950","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614059950?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:12","pubTimestamp":1772053921,"startTime":"0","endTime":"0","summary":"“We made substantial clinical progress over the past year continuing to advance our broad portfolio of RAS(ON) inhibitors across multiple tumor typ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-reports-q4-eps-1-86-consensus-1-56-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-reports-q4-eps-1-86-consensus-1-56-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"gpt_icon":0},{"id":"2614059679","title":"Revolution Medicines sees FY26 operating expenses $1.6B-$1.7B","url":"https://stock-news.laohu8.com/highlight/detail?id=2614059679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614059679?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:11","pubTimestamp":1772053894,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) expects full year 2026 GAAP operating expenses to be between $1.6 and $1.7 billion, which includes estimated non-cash s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-sees-fy26-operating-expenses-1-6b-1-7b-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-sees-fy26-operating-expenses-1-6b-1-7b-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"gpt_icon":0},{"id":"2614056977","title":"Revolution Medicines Q4 EPS $(1.86) Misses $(1.58) Estimate. Cash And Equivalents $2.03B","url":"https://stock-news.laohu8.com/highlight/detail?id=2614056977","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614056977?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:10","pubTimestamp":1772053841,"startTime":"0","endTime":"0","summary":"Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.86) per share which missed the analyst consensus estimate of $(1.58) by 17.87 percent. This is a 66.07 percent decrease over losses of $(1.12) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50867194/revolution-medicines-q4-eps-1-86-misses-1-58-estimate-cash-and-equivalents-2-03b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Q4 EPS $(1.86) Misses $(1.58) Estimate. Cash And Equivalents $2.03B","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com","stockEarnings":[{"period":"1week","weight":-0.02},{"period":"1month","weight":0.0482},{"period":"3month","weight":0.3494},{"period":"6month","weight":1.5552},{"period":"1year","weight":1.4944},{"period":"ytd","weight":0.2758}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.025703},{"month":4,"riseRate":0.666667,"avgChangeRate":0.052764},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.03349},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042659},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000709},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}